16 / 30
Cabozantinib
(N=470)
Placebo
(N=237)
ORR, %
4
0.4
95% CI
2–6
0–2
p-value*
0.009
Best overall response, %
Complete response
0
0
Partial response
4
<1
Stable disease
60
33
Progressive disease
21
55
Not evaluable or missing
15
11
CELESTIAL Phase III study: Efficacy